Last reviewed · How we verify
Imuran
At a glance
| Generic name | Imuran |
|---|---|
| Also known as | Azathioprine |
| Sponsor | Baylor Research Institute |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING - MALIGNANCY Chronic immunosuppression with IMURAN, a purine antimetabolite increases risk of malignancy in humans. Reports of malignancy include post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. Physicians should inform patients of the risk of malignancy with
Common side effects
- Nausea and vomiting
- Leukopenia
- Thrombocytopenia
- Infection
- Macrocytic anemia
- Bleeding
- Diarrhea
- Fever
- Malaise
- Myalgias
- Skin rashes
- Alopecia
Serious adverse events
- Myelosuppression (severe, life-threatening)
- Lymphoproliferative disease
- Hepatic veno-occlusive disease
- Hepatosplenic T-cell lymphoma
- Pancreatitis (hypersensitivity)
- Reversible interstitial pneumonitis
- Sweet's Syndrome (acute febrile neutrophilic dermatosis)
- Secondary malignancy
- Secondary infection
Key clinical trials
- Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease (PHASE3)
- Combined Immunosuppression for Pediatric Crohn's Disease (PHASE4)
- This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis
- The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children (NA)
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2) (PHASE3)
- An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis (PHASE2)
- Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |